drugset / Trial / NCT05732831
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
Timeline
- Start
- 2023-05-26
- Primary completion
- 2027-06
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | TNG462 | Unknown | — | Oral |
Indications
No indication recorded.